Cofttek holdings limited

MEK&P38 MAPK

AZD8330 (869357-68-6)

R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38α.AZD8330, also known as ARRY704 and ARRY424704, is an orally active, selective MEK inhibitor with potential antineoplastic activity.

Not Intended for Therapeutic Use. For research use only.

CAS: 869357-68-6 Category

AZD8330 (869357-68-6) Description:

AZD8330, also known as ARRY704 and ARRY424704, is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

ZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

AZD8330 (869357-68-6) Specifications:

Product Name AZD-8330
Synonym AZD8330; AZD-8330; AZD 8330; ARRY424704; ARRY 424704; ARRY-424704; ARRY704; ARRY-704; ARRY 704.
Chemical Name 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide.
Drug Class N/A
Purity >98% (or refer to the Certificate of Analysis)
CAS Number 869357-68-6
Molecular Formula C16H17FIN3O4
Molecular Weight 461.23
Monoisotopic Mass
461.025 g/mol

 

MDL number MFCD18384989
InChIKey RWEVIPRMPFNTLO-UHFFFAOYSA-N
InChi Code InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)
SMILES O=C(C(C=C1C)=C(NC2=CC=C(I)C=C2F)N(C)C1=O)NOCCO
Form solid powder
Color N/A
Solubility  Soluble in DMSO, not soluble in water.
Storage Temp.  Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shelf life >2 years if stored properly
Handling Protect from air and moisture
Application R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38α.

 


=

RIDADR NONH for all modes of transport

References:

  • 1. TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies. Wang J, Liang X, Yu T, Xu YL, Xu LH, Zhang XJ, Ma J, Wang YR, He SL. Cell Biol Int. 2018 Nov;42(11):1503-1510. doi: 10.1002/cbin.11035. Epub 2018 Sep 11.
  • 2.MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Baranski Z, Booij TH, Kuijjer ML, de Jong Y, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH. Genes Cancer. 2015 Nov;6(11-12):503-12.
  • 3. [Effect of ERK1/2 inhibitor AZD8330 on human Burkitt’s lymphoma cell line Raji cells and its mechanism].Feng K, Wang C, Zhou H, Yang J, Dong L, Zhou K, Liu X, Song Y. Zhonghua Xue Ye Xue Za Zhi. 2015 Feb;36(2):148-52. doi: 10.3760/cma.j.issn.0253-2727.2015.02.014. Chinese.
  • 4. [Effect of AZD8330 on proliferation and apoptosis of multiple myeloma cells]. Yao Y, Bian YP, Xia DD, Pan B, Niu MS, Zhao K, Zeng LY, Xu KL. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1311-5. doi: 10.7534/j.issn.1009-2137.2014.05.024. Chinese.
  • 5. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. Eur J Cancer. 2013 May;49(7):1521-9. doi: 10.1016/j.ejca.2013.01.013. Epub 2013 Feb 21.

1 review for AZD8330 (869357-68-6)

  1. Cofttek

    Never had such good experience before,The AZD8330 (869357-68-6) is high purity,also customer service is pretty nice !gotta try!!

Add a review

Your email address will not be published. Required fields are marked *